Hematological Toxicity of PARP Inhibitors in Metastatic Prostate Cancer Patients with Mutations of BRCA or HRR Genes: A Systematic Review and Safety Meta-analysis

[1]  L. Antonuzzo,et al.  Personalized Medicine for Metastatic Prostate Cancer: The Paradigm of PARP Inhibitors. , 2023, Critical reviews in oncology/hematology.

[2]  N. Lawrentschuk,et al.  Combination treatment in metastatic prostate cancer: is the bar too high or have we fallen short? , 2022, Nature Reviews Urology.

[3]  W. Chua,et al.  Review of Toxicities of PARP Inhibitors in Metastatic Castrate Resistant Prostate Cancer. , 2022, Clinical genitourinary cancer.

[4]  A. Jemal,et al.  Cancer statistics, 2022 , 2022, CA: a cancer journal for clinicians.

[5]  Jing Li,et al.  Haematologic toxicities with PARP inhibitors in cancer patients: an up‑to‑date meta‑analysis of 29 randomized controlled trials , 2021, Journal of clinical pharmacy and therapeutics.

[6]  V. Conteduca,et al.  New Prognostic Biomarkers in Metastatic Castration-Resistant Prostate Cancer , 2021, Cells.

[7]  E. Mayo-Wilson,et al.  The PRISMA 2020 statement: an updated guideline for reporting systematic reviews , 2020, BMJ.

[8]  G. Tonini,et al.  The emerging role of PARP inhibitors in prostate cancer , 2020, Expert review of anticancer therapy.

[9]  F. Saad,et al.  Pre-specified interim analysis of GALAHAD: A phase II study of niraparib in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and biallelic DNA-repair gene defects (DRD) , 2019, Annals of Oncology.

[10]  J. Ledermann,et al.  Safety and dose modification for patients receiving niraparib , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[11]  S. Lawo,et al.  Evaluation of clinical-stage PARP inhibitors in cell-based assays to correlate PARP suppression with functional impact on DNA repair , 2016 .

[12]  David C. Smith,et al.  Integrative Clinical Genomics of Advanced Prostate Cancer , 2015, Cell.

[13]  J. Yélamos,et al.  PARP-2 sustains erythropoiesis in mice by limiting replicative stress in erythroid progenitors , 2014, Cell Death and Differentiation.

[14]  Benjamin J. Raphael,et al.  The Mutational Landscape of Lethal Castrate Resistant Prostate Cancer , 2012, Nature.

[15]  J. Sterne,et al.  The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials , 2011, BMJ : British Medical Journal.

[16]  S. Thompson,et al.  Quantifying heterogeneity in a meta‐analysis , 2002, Statistics in medicine.

[17]  N. Laird,et al.  Meta-analysis in clinical trials. , 1986, Controlled clinical trials.

[18]  W. G. Cochran.  The combination of estimates from different experiments. , 1954 .